参考文献/References:
[1] Garg V. Noninsulin pharmacological management of type 1 diabetes mellitus[J]. Indian J Endocrinol Metab,2011,15(Suppl 1): S5-S11.
[/br][2] Liu C, Wu D, Zheng X, et al. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis[J]. Diabetes Technol Ther, 2015,17(2):142-148.
[/br][3] Bhat R, Bhansali A, Bhadada S, et al. Effect of pioglitazone therapy in lean type 1 diabetes mellitus[J].Diabetes Res Clin Pract,2007,78(3): 349-354.
[/br][4] Shimada A, Shigihara T, Okubo Y,et al. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes[J]. Diabetes Metab Res Rev,2011, 27(8): 951-953.
[/br][5] Juntti-Berggren L, Pigon J, Hellström P,et al. Influence of acarbose on post-prandial insulin requirements in patients with type 1 diabetes[J]. Diabetes Nutr Metab,2000,13(1): 7-12.
[/br][6] Nagai E, Katsuno T, Miyagawa J, et al. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus[J]. Endocr J, 2011, 58(10): 869-877.
[/br][7] Varanasi A, Bellini N, Rawal D,et al. Liraglutide as additional treatment for type 1 diabetes[J].Eur J Endocrinol,2011, 165(1): 77-84.
[/br][8] Kielgast U, Krarup T, Holst JJ,et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function[J]. Diabetes Care, 2011,34(7):1463-1468.
[/br][9] Ellis SL, Moser EG, Snell-Bergeon JK,et al. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized,crossover trial[J].Diabet Med,2011, 28(10):1176-1181.
[/br][10] Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study[J]. J Clin Endocrinol Metab, 2014,99(5):E876-E880.
[/br][11] Schopman JE, Hoekstra JB, Frier BM,et al. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study[J].Diabetes Obes Metab, 2015,17(6):546-553.
[/br][12] Ceriello A, Novials A, Ortega E,et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes[J]. Diabetes Care, 2013,36(8):2346-2350.
[/br][13] Young A. Amylin and the integrated control of nutrient influx[J].Adv Pharmacol,2005, 52: 67-77.
[/br][14] Ratner R, Whitehouse F, Fineman MS,et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets[J].Exp Clin Endocrinol Diabetes,2005, 113(4):199-204.
[/br][15] Pencek R, Roddy T, Peters Y,et al. Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study[J].Diabetes Obes Metab,2010,12(6):548-551.
[/br][16] Sorensen JS, Birkebaek NH, Bjerre M, et al. Residual β-cell function and the insulin-like growth factor system in Danish children and adolescents with type 1 diabetes[J]. J Clin Endocrinol Metab, 2015,100(3):1053-1061.
[/br][17] Ludvigsson J. The latest pharmacotherapy options for type 1 diabetes[J]. Expert Opin Pharmacother, 2014,15(1):37-49.
[/br][18] Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes [J]. Expert Opin Investig Drugs,2014,23(6):875-882.
[/br][19] Orban T, Bundy B, Becker DJ,et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial[J].Lancet, 2011,378(9789):412-419.
[/br][20] Keymeulen B,Walter M, Mathieu C,et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass[J]. Diabetologia, 2010,53(4):614-623.
[/br][21] Sherry N, Hagopian W, Ludvigsson J,et al. Teplizumab for treatment of type 1 diabetes(Protégé study): 1-year results from a randomised, placebo-controlled trial[J].Lancet,2011,378(9790):487-497.
[/br][22] Demeester S, Keymeulen B, Kaufman L, et al. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes[J].Diabetes Care,2015,38(4):644-651.
[/br][23] Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment[J].Diabetes Care, 2014,37(4):1069-1075.
[/br][24] Sumpter KM, Adhikari S, Grishman EK, et al. Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes[J].Pediatr Diabetes,2011,12(7):656-667.
[/br][25] Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials[J].Lancet,2013,381(9881):1905-1915.
[/br][26] Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes(T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial[J].Lancet Diabetes Endocrinol,2013,1(4):284-294.
[/br][27] Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results[J].Diabetes Care, 2014,37(2):453-459.
相似文献/References:
[1]袁扬,孙子林.PANDER与β细胞凋亡[J].国际内分泌代谢杂志,2007,(04):253.
[2]刘媛 刘超.1型糖尿病青少年儿童心理行为问题研究进展[J].国际内分泌代谢杂志,2015,(01):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
Liu Yuan,Liu Chao..Psychological problems in adolescents and children with type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(06):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
[3]王思倩,吴锦丹.肠促胰素对1型糖尿病患者血糖及胰岛功能的影响[J].国际内分泌代谢杂志,2015,(03):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
Wang Siqian,Wu Jindan..Effects of incretin on blood glucose and islet function in type 1 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(06):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
[4]李亚兰,项洁,卜瑞芳.1型糖尿病的DiaPep277免疫治疗[J].国际内分泌代谢杂志,2014,(03):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
Li Yalan,Xiang Jie,Bu Ruifang..Immunotherapy with DiaPep277 peptide in type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2014,(06):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
[5]陈晔,李艳玲,王坚.天然免疫细胞在1型糖尿病中的作用[J].国际内分泌代谢杂志,2014,(03):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
Chen Ye,Li Yanling,Wang Jian..Role of innate immune cells in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(06):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
[6]王静 张梅.胰高血糖素在1型糖尿病治疗中的研究进展[J].国际内分泌代谢杂志,2018,38(01):19.[doi:10.3760/cma.j.issn.1673-4157.2018.01.005]
Wang Jing,Zhang Mei.Research progress of glucagon for the treatment of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(06):19.[doi:10.3760/cma.j.issn.1673-4157.2018.01.005]
[7]朱婧 蒋晓红 项守奎 许晨 华飞.1型糖尿病患者尿酸水平与血脂异常的
相关性研究[J].国际内分泌代谢杂志,2020,40(01):16.[doi:10.3760/cma.j.issn.1673-4157.2020.01.004]
Zhu Jing,Jiang Xiaohong,Xiang Shoukui,et al.Correlation between uric acid level and dyslipidemia in patients with type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2020,40(06):16.[doi:10.3760/cma.j.issn.1673-4157.2020.01.004]
[8]周小海,安晔,王小玲,等.1型糖尿病合并非酒精性脂肪性肝病与慢性肾脏病的关系[J].国际内分泌代谢杂志,2021,41(04):339.[doi:10.3760/cma.j.cn121383-20200713-07032]
Zhou Xiaohai,An Ye,Wang Xiaoling,et al.Relationship between nonalcoholic fatty liver disease and chronic kidney disease in patients with type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(06):339.[doi:10.3760/cma.j.cn121383-20200713-07032]
[9]陈双,杨涛,顾愹.1型糖尿病的诊断与免疫治疗[J].国际内分泌代谢杂志,2021,41(06):578.[doi:10.3760/cma.j.cn121383-20210915-09046]
Chen Shuang,Yang Tao,Gu Yong..Diagnosis and immunotherapy of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(06):578.[doi:10.3760/cma.j.cn121383-20210915-09046]
[10]齐晓洁,苏恒.1型糖尿病的二级预防临床研究进展[J].国际内分泌代谢杂志,2022,42(03):187.[doi:10.3760/cma.j.cn121383-20210129-01088]
Qi Xiaojie,Su Heng..Progress in secondary prevention of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2022,42(06):187.[doi:10.3760/cma.j.cn121383-20210129-01088]